-
公开(公告)号：EP1812593A2
公开(公告)日：2007-08-01
申请号：EP05803956.1
申请日：2005-11-10
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
CPC分类号： C12Q1/6883 , C07K14/47 , C12Q2600/106 , C12Q2600/156 , G01N33/5008 , G01N33/5011 , G01N33/68 , G01N33/6848 , G01N2800/52
摘要： The present invention relates to methods for determining the potential of a subject to respond to a particular therapeutic agent, by determining the presence of one or more nucleotide or amino acid variants in the β-tubulin gene or protein. Also provided are methods for treating subjects whose potential to respond to a therapeutic agent has been evaluated. For use in the methods of the invention, there are provided variants of the β-tubulin gene, variants of the β-tubulin protein, nucleic acid molecules and agents which bind to the variant β-tubulin nucleic acid molecules and variant β-tubulin protein, respectively, and kits comprising the same.
摘要翻译： 本发明涉及通过确定β-微管蛋白基因或蛋白质中一种或多种核苷酸或氨基酸变体的存在来确定受试者对特定治疗剂作出反应的潜力的方法。 还提供了用于治疗对治疗剂有反应潜力的受试者的方法。 为了用于本发明的方法，提供了β-微管蛋白基因的变体，β-微管蛋白的变体，核酸分子和结合变体β-微管蛋白核酸分子和变体β-微管蛋白蛋白的试剂 ，以及包含它们的试剂盒。
-
公开(公告)号：EP1412029A2
公开(公告)日：2004-04-28
申请号：EP02764726.2
申请日：2002-07-18
申请人： Novartis AG , Novartis Pharma GmbH
发明人： CHEN, TianLing , GREELEY, Diane , ROTHERMEL, John, David , WARTMANN, Markus , WOOD, Jeanette, Marjorie
IPC分类号： A61P35/00 , A61K31/427 , A61K31/282 , A61K33/24 , A61K31/4439 , A61K31/663
CPC分类号： A61K31/663 , A61K31/427 , A61K31/502 , A61K31/555 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula (I), wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.
-
公开(公告)号：EP1363996A2
公开(公告)日：2003-11-26
申请号：EP01997543.2
申请日：2001-11-20
CPC分类号： G01N33/5011 , A61K47/6803 , A61K47/6851 , C12N5/0693 , C12N2503/02 , G01N33/5008 , G01N33/5014
摘要： Epothilone resistant cells lines are disclosed. The invention also discloses methods for identifying substances which are cytotoxic to epothilone resistant cells or which are chemosensitizers or analogs of epothilone. The invention further discloses methods for identifying epothiolone resistant cells and for inhibiting the growth of epothilone resistant cells in vitro and in vivo. The invetion also discloses antibodies specific for epothilone resistant cells. Also disclosed is a method to identify microtubule stabilizing agents using the epothilone resistant cell lines disclosed.
-
公开(公告)号：EP3273959A1
公开(公告)日：2018-01-31
申请号：EP16712083.1
申请日：2016-03-23
申请人： NOVARTIS AG
发明人： BUSCHMANN, Nicole , FAIRHURST, Robin Alec , FURET, Pascal , KNOEPFEL, Thomas , LEBLANC, Catherine , MAH, Robert , LIAO, Lv , XIONG, Jing , HAN, Bo , WANG, Can , GRAUS PORTA, Diana , ZHAO, Xianglin , WARTMANN, Markus , FORTANET, Jorge Garcia , HAFEEZ, Nafeeza , LAMARCHE, Matthew J. , PORTER, Dale
IPC分类号： A61K31/506 , A61K31/4439 , A61K31/513 , A61K31/519 , A61K31/5377 , A61P35/00
CPC分类号： A61K31/496 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K2300/00
摘要： A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
-
公开(公告)号：EP1056453B1
公开(公告)日：2010-10-06
申请号：EP99910257.7
申请日：1999-02-23
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： A61K31/425
CPC分类号： A61K31/425
-
16.发明授权COMBINATION COMPRISING N- 5- 4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO|-2-METHYLPHENYL -4-(3-PYRIDYL)-2PYRIMIDINE-AMINE AND A BIPHOSPHONATE 有权COMBINATION N- 5-（4-甲基 - 哌嗪子基 - 甲基） - 苯甲酰胺基具有二膦酸酯-2-甲基-4-（3-吡啶基）-2PYRIMIDINE胺
公开(公告)号：EP1392313B1
公开(公告)日：2007-04-18
申请号：EP02743024.8
申请日：2002-05-15
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BRUNS, Christian , BUCHDUNGER, Elisabeth , O'REILLY, Terence , SILBERMAN, Sandra, Leta , WARTMANN, Markus , WECKBECKER, Gisbert
IPC分类号： A61K31/506 , A61P35/00 , A61P37/06 , A61K31/675
CPC分类号： A61K45/06 , A61K31/506
摘要： A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.
-
17.发明公开USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS 审中-公开ALPHA-微管蛋白乙酰ALS BIOANZEIGER用于蛋白质去乙酰化酶抑制剂的用途
公开(公告)号：EP1456664A1
公开(公告)日：2004-09-15
申请号：EP02795117.7
申请日：2002-12-06
申请人： Novartis AG , Novartis Pharma GmbH
发明人： ATADJA, Peter, Wisdom , HOVING, Sjouke , TOWBIN, Harry , WALKER, Heather Brownlee , WARTMANN, Markus , YELESWARAPU, Lakshmi
IPC分类号： G01N33/574 , G01N33/50 , G01N33/68 , G01N33/53
CPC分类号： G01N33/5011 , G01N33/574 , G01N2333/916 , G01N2500/10
摘要： The invention relates to a novel method for evaluating the antiproliferative activity of protein deacetylase inhibiting compounds and microtubule interacting agents, as well as a method for screening for compounds that inhibit cell growth or growth of tumors. The invention additionally provides a method for monitoring the progress of treatment against cellular growth or the growth of tumors.
-
18.发明公开COMBINATION COMPRISING N- 5- 4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL -4-(3-PYRIDYL)-2PYRIMIDINE-AMINE AND A CHEMOTHERAPEUTIC AGENT 有权COMBINATION N- 5-（4-甲基 - 哌嗪子基 - 甲基） - 苯甲酰胺基具有二膦酸酯-2-甲基-4-（3-吡啶基）-2PYRIMIDINE胺
公开(公告)号：EP1392313A1
公开(公告)日：2004-03-03
申请号：EP02743024.8
申请日：2002-05-15
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BRUNS, Christian , BUCHDUNGER, Elisabeth , O'REILLY, Terence , SILBERMAN, Sandra, Leta , WARTMANN, Markus , WECKBECKER, Gisbert
IPC分类号： A61K31/506 , A61P35/00 , A61P37/06
CPC分类号： A61K45/06 , A61K31/506
摘要： A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.
-
公开(公告)号：EP1198225A1
公开(公告)日：2002-04-24
申请号：EP00949439.4
申请日：2000-08-02
申请人： Novartis AG
IPC分类号： A61K9/127 , A61K31/425
CPC分类号： A61K9/127 , A61K9/1271 , A61K31/427
摘要： This invention provides liposomal compositions comprising an epothilone.
-
公开(公告)号：EP1056453A1
公开(公告)日：2000-12-06
申请号：EP99910257.7
申请日：1999-02-23
IPC分类号： A61K31/425
CPC分类号： A61K31/425
摘要： The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.025 秒)
